An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Prior treatment

• Has received cemiplimab prior to enrollment
• Is concurrently participating in any other study of an investigational drug or procedure

Other illness

• Has uncontrolled autoimmune disease
• Has cognitive impairment or other medical condition that, in the opinion of the investigator, would interfere with the ability to complete the study-related questionnaires
  • NOTE: Other protocol-defined inclusion/exclusion criteria apply

Other

• Has a contraindication to cemiplimab as noted in the local SmPC

• At least 18 years of age at the time of cemiplimab treatment initiation
• Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC
• Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).
• Can understand and complete the study-related questionnaires
• Must be legally capable of providing written consent for participation in the study and have signed informed consent prior to any study activities